HDMA announces 2014 DIANA Winners
ARLINGTON, Va. — HDMA on Tuesday honored pharmaceutical and consumer product manufacturers at its 2014 Business and Leadership Conference in Phoenix, through the presentation of the Association’s annual Distribution Industry Awards for Notable Achievements in Healthcare (the DIANA awards).
The DIANA awards have recognized supply chain excellence and successful trading partner relationships since 1959. The awards honor pharmaceutical and consumer product manufacturers for developing innovative new product introductions and promotions for the healthcare distribution industry. Manufacturers also are recognized for advancing trade relations by fostering strong trading partner relationships with HDMA distributor members and creating exceptional business practices that benefit the entire healthcare supply chain.
In addition, presented for the second year, the DIANA Manufacturer Partner of the Year recognizes companies for their active participation in the Association. The winning companies have at least five consecutive years of membership, regularly participate in HDMA conferences, serve on Association committees, and show support through event attendance and sponsorships.
2014 DIANA Manufacturer Partner of the Year Winners:
- HDMA Manufacturer Member With Sales to Healthcare Distributors of More Than $50 Million: Mylan
- HDMA Manufacturer Member With Sales to Healthcare Distributors of Less Than $50 Million: Upsher-Smith Laboratories.
2014 DIANA Winners:
Best New Product Introduction or Promotion Awards:
- Branded Pharmaceutical Products: Eisai for Belviq;
- Generic Pharmaceutical Products: Citron Pharma for duloxetine DR capsules USP; and
- Over-the-Counter and Home Healthcare Products: Merck Consumer Care, for Oxytrol for Women.
Best Overall Manufacturer Awards:
- Branded Pharmaceutical Product Manufacturer with Sales to Healthcare Distributors of Less Than $300 Million: Depomed;
- Branded Pharmaceutical Product Manufacturer with Sales to Healthcare Distributors of More Than $300 Million: Forest Pharmaceuticals;
- Generic Pharmaceutical Product Manufacturer with Sales to Healthcare Distributors of Less Than $100 Million: Alvogen;
- Generic Pharmaceutical Product Manufacturer with Sales to Healthcare Distributors of More Than $100 Million: Actavis; and
- Consumer Product Manufacturer: BD Medical – Diabetes Care.
Crystal Light, Miranda Lambert to go ‘Platinum’ this summer
NORTHFIELD, Ill. — Crystal Light, a brand from Kraft Foods Group, on Monday announced a partnership with singer-songwriter Miranda Lambert for her upcoming "Platinum" tour. The brand will serve as presenting sponsor for the Grammy Award-winning artist.
The Crystal Light Presents "Platinum" Tour will kick off on July 10 and visit 30 cities throughout the United States this summer. The brand will host several engagement areas at select venues. Concertgoers will be able to sample products and take advantage of giveaways.
"Crystal Light is about adding fun, guilt-free pleasure to your day, so teaming up with Miranda Lambert, a long-time fan of the brand, was a natural fit for us," said Jennifer Dahlgren, senior brand manager for Crystal Light. "We’re excited to accompany Miranda on her tour during such an exciting time in her career, and join her amazing fans in a celebration across the country this summer."
Actavis reaches agreement with Cephalon over patent
DUBLIN — Actavis last week announced that it has reached an agreement with Cephalon to settle all outstanding patent litigation associated with Actavis’ generic version of Nuvigil (armodafinil tablets).
As part of the agreement, Cephalon will allow Actavis to market generic versions of 100-mg and 200-mg Nuvigil beginning June 1, 2016 or earlier under certain conditions. Cephalon also will grant Actavis a license to market generic versions of 50-mg, 150-mg and 250-mg Nuvigil beginning 180 days after the initial launch of the generic versions of those strenghts. Additional details were not disclosed.
Nuvigil is used to improve wakefulness in patients with excessive sleepiness associated with obstructive sleep apnea, shift work disorder or narcolepsy, the company stated. Nuvigil had sales in the United States of approximately $437 million for th 12 months ending Feb. 28, according to IMS Health data.